Amifostine is a pharmacological antioxidant used as a cytoprotectant in cancer chemotherapy and radiotherapy. It is thought to protect normal tissues relative to tumor tissue against oxidative damage inflicted by cancer therapies by becoming concentrated at higher levels in normal tissues. The degree to which amifostine nevertheless accumulates in tumors and protects them against cancer therapies has been debated. Guidelines have been published that direct its use in chemotherapy and radiation, taking into consideration the concerns of tumor protection. In this article, clinical studies of amifostine appearing since the publication of the most recent set of guidelines are reviewed. Randomized and nonrandomized trials of regimens involving chemotherapeutic agents (chemotherapy, chemoradiation, conditioning regimens for bone marrow transplant) are discussed. Nineteen studies showed positive effects for amifostine reducing the level of side effects of these regimens, while 9 showed no effect and 1 had a questionable result. Clinically relevant levels of amifostine toxicity were observed in several studies, but subcutaneous administration may reduce such toxicity. Amifostine showed protection against mucositis, esophagitis, neuropathy, and other side effects, although protection against cisplatin-induced ototoxicity was not observed. No evidence of tumor protection was observed. Amifostine may enable populations unable to tolerate conventional cancer therapy to receive treatment of their cancers, even if some degree of tumor protection is eventually discovered. The authors discuss the implications of this research for patient populations seen in integrative cancer care centers and for research on phytochemical antioxidants such as vitamins and carotenoids.
The use of antioxidants during chemotherapy and radiation therapy has been a continuing area of concern in integrative oncology. 1 The recent publication of the study by Bairati et al, in which 540 patients with head and neck cancer undergoing radiation therapy were given supplements of 400 IU daily of αtocopherol and 30 mg β-carotene, has stimulated further debate on this issue. 2 This study was begun before the publication of results indicating potentially harmful effects of β-carotene. The 2 supplements, when administered together, were associated with lower rates of adverse effects to the larynx and overall at any site. However, β-carotene dosing was stopped during the study due to the emergence of its potential for adverse prooxidant effects. α-Tocopherol alone had no protective effects on normal tissue. A trend (not significant) for higher rates of local recurrence in the supplemented group was evident, to a greater extent in patients who had received β-carotene (HR 1.37) than in those who received only α-tocopherol (HR 1.29), implying that the antioxidant supplements may protect tumor tissues from radiation, as well as normal tissues.
The use of single antioxidant supplements during chemotherapy or radiation has been vigorously debated in recent years; Prasad, among others, has argued that use of single agents is counterproductive and that multiple antioxidant vitamins must be used in such circumstances. 3 A recent trial conducted in India by Pathak et al, involving 136 patients with advanced head and neck cancers supplemented with ascorbic acid, α-tocopherol, and β-carotene, found a slight but nonsignificant advantage in overall 1-year survival (32.9% without vs 39.1% with antioxidants) for the supplemented group. 4 Although toxicity profiles were similar, the authors argue that the study demonstrates the possibility that a larger trial may demonstrate significantly improved survival.
The Bairati and Pathak studies examine the use of phytochemical antioxidants (carotenoids and tocopherols, ascorbic acid) as cytoprotectants, as well as nutritional agents. The use of cytoprotectants, agents that protect normal tissue from the effects of chemotherapy and radiation, has been the subject of substantial controversy over the past 2 decades with synthetic compounds such as mesna, dexrazoxane, and amifostine, due to their potential impact on protection of malignant tissue. Such cytoprotection is favorable for diminishing toxicity to normal tissue but could potentially interfere with treatment of malignant tissue (on the other hand, there is evidence suggesting that antioxidants may be protective to normal tissue, such as that discussed by Prasad et al 3 ). As integrative oncology researchers embark on further studies of antioxidant cytoprotection, it may be wise for them to consider the issues that have arisen and been discussed in this area. We here review the history and current research trends on one of the most controversial of these agents, amifostine. Amifostine itself is of clinical interest in integrative practice, and a review of current research on its use may be in order for clinicians in whose institutions it is being used or considered. For the purposes of this article, we will consider the use of amifostine in protocols that involve chemotherapy-standard chemotherapy, chemoradiation, and high-dose conditioning for bone marrow transplant.
History of Amifostine
Amifostine (Ethyol, WR-2721; Medimmune, Gaithersburg, Md) is a by-product of the cold war. Initially developed in attempts to protect persons exposed to nuclear fallout, it was later found to offer relative radioprotection to normal cells at the expense of tumor cells and then developed as an intravenous cytoprotectant for use in radiation therapy and chemotherapy. Amifostine is a phosphorylated thiol prodrug: its active metabolite WR-1065 is dephosphorylated by membrane-bound alkaline phosphatase.
The relative cytoprotection for normal cells emerges from the higher concentrations of WR-1065 that build up in normal versus tumor cells. Normal tissue has higher levels of alkaline phosphatase throughout, including in epithelium, connective tissue, and vasculature, whereas in the tumor, including the stroma and vessels, concentrations are much lower. Thus, the conversion of WR-1065 is higher in normal than in tumor tissue. 5 The restricted and abnormal vasculature of tumors, or postsurgical disruption of blood circulation, may block blood flow to tumor tissue, thus resulting in lower concentrations even of the prodrug. Low pH in tumors, as well as hypoxia, may also reduce formation of WR-1065. Once inside the cell, WR-1065 acts as an antioxidant, scavenging free radicals, decreasing the interstrand cross-links caused by alkylating agents and decreasing platinum-DNA adducts. 6 Facorro et al, for instance, recently confirmed the free radical scavenging activity of amifostine in the situation of total body irradiation (TBI) for bone marrow transplant patients. 7 TBI is known to produce reactive oxygen species, but in patients treated with amifostine prior to TBI, reactive oxygen species were absent from plasma samples analyzed by electron spin resonance spectroscopy and spin resonance techniques, while they were present in untreated patients, who also had higher rates of severe mucositis and longer hospitalizations after transplant.
Like other cytoprotectants, though, amifostine has raised concerns about tumor protection (the protection of the tumor against the therapeutic effects of radiation or chemotherapy by the antioxidant active drug). Although theoretically, the concentration of the active drug in tumors should be negligible, some preclinical research has shown detectable amifostine in tumor tissue or even outright tumor protection in animal studies, as indicated by higher rates of response to radiation or chemotherapy in untreated animals. Koukourakis, for instance, in a 2003 review that is positive toward the use of amifostine, nevertheless listed 19 animal studies in which there was no evidence of tumor protection (or treatment interference) by amifostine and 10 studies in which tumor protection was shown. 5 He also discussed 2 studies that have been quite influential in the tumor protection debate. A controlled study conducted in dogs with spontaneous sarcomas, treated with radiation and with or without amifostine, found no evidence of protection of normal tissues and reported local control data that were interpreted as evidence of tumor protection. 8 While this 1986 study considerably diminished enthusiasm for amifostine, Koukourakis recounted several criticisms of the work, including differences in the radiosensitivity of the histologic types of tumors in the amifostine and control animals. An animal study on amifostine and ormaplatin that indicated a potential pharmacokinetic interaction between the 2 drugs also raised considerable controversy: complexes of an ormaplatin metabolite and WR-1065 were noted, which inactivated the metabolite. Although this study was also criticized on several grounds, controversy continued about amifostine as a cytoprotectant, stimulating Lindegaard and Grau in 2000 to suggest-well after approval of amifostine by the Food and Drug Administration (FDA)-that it be not used other than in clinical trials and not in routine clinical practice. 9 
Toxicity of Amifostine Hypotension
Both logistical issues and significant toxicities associated with intravenous (IV) administration made amifostine difficult to incorporate into clinical practice. Amifostine has typically been administered IV over the course of 10 to 15 minutes or by IV push over a shorter period. This administration must take place less than half an hour before the anticipated radiation or chemotherapy treatment. Scheduling this additional treatment has resulted in various difficulties for clinical trials, especially those involving hyperfractionated radiation doses: the question arises whether amifostine needs to be given twice daily, before each radiation dose, or whether a single daily administration is sufficient. A major toxicity of amifostine, hypotension, further complicates the administration. To reduce the risk of hypotension, 500 to 1000 mL saline is usually given IV prior to amifostine. Usual antihypertensive medication may be withheld the day of the amifostine infusion. The drug is usually administered while the patient is supine. Blood pressure is monitored every 3 to 5 minutes until at least 5 minutes after the infusion. Typically, if the systolic blood pressure falls more than 20% below baseline, the amifostine infusion is interrupted until it returns to normal. Symptomatic patients may also be placed in the Trendelenberg position. If blood pressure does not return to normal quickly, or if the infusion is interrupted more than once or twice, typical practice is to discontinue the amifostine and attempt to administer it again before the next scheduled radiation or chemotherapy dose. If 2 episodes of toxicity occur, amifostine may best be discontinued altogether.
Other Systemic Toxicities
Further toxicities also complicate the intravenous administration of amifostine, although subcutaneous (SC) administration (to be discussed in more detail below) may be found to ease this problem. Hypocalcemia occurs in some patients, and calcium supplementation is given when this occurs. Nausea and vomiting are frequent. Most studies include administration of dexamethasone and/or serotonin receptor antagonist antiemetics before amifostine to reduce toxicity. Allergies, including anaphylaxis, are observed in some patients, so antihistamine therapy may be given as well. Despite the use of various strategies to prevent toxic reactions, the rate of amifostine toxicity can be substantial. Rades et al, for instance, reported on a phase III radiotherapy and chemotherapy study in head and neck cancer patients that was stopped after 41% of patients experienced amifostine toxicity at high enough levels (grades 2-3) that they had to discontinue amifostine treatment. 10 Vomiting, hypotension, and allergic reactions were the main reasons for discontinuation. Amifostine toxicity was significantly associated with chemotherapy use (which was optional during the trial). Although this trial did not give antihistamines before amifostine, did not report withholding antihypertensives, and made ondansetron available only when patients were experiencing nausea rather than giving antiemetics routinely, the authors reviewed 3 other amifostine studies on head and neck cancer patients in the literature, in which amifostine discontinuation rates ranged from 11% to 38%. No long-term side effects from amifostine are reported from these trials. While most trials report less toxicity than this in using amifostine, the problem of amifostine toxicity is significant and has adversely affected quality of life in some trials.
Skin Toxicities
Local reactions to amifostine at the injection site are possible and are not considered severe. Reports of severe skin toxicities following amifostine treatment, however, stimulated the manufacturer of amifostine to convene an expert panel to examine the reports and come to a conclusion about the reality of their association with amifostine, as well as develop guidelines for managing them. 11 A total of 35 reports of reactions classified as erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, and bullae were reported. A rate of 0.8 to 1 patient per 10 000 chemotherapy patients and 6 to 9 per 10000 radiotherapy patients was calculated. Practitioners who use amifostine are advised to evaluate for skin reactions before amifostine administration, being particularly aware of reactions involving the lips or mucosa that are not from other treatments (eg, radiation mucositis) and any that are associated with fever or constitutional symptoms or any other severe symptoms not known to be due to another etiology. If such are found, amifostine treatment should be not be started or should be discontinued.
SC Administration of Amifostine
SC administration appears to have provided a considerable improvement in amifostine toxicity. This has been explored in several studies. Koukourakis same level, as well as giving additional patients SC amifostine only. 12 In the patients receiving IV amifostine, 13.5% developed protracted vomiting, malaise, or hypotension within 2 cycles. With SC delivery, such symptoms were completely absent. Bonner et al reported a small pilot study of oral, SC, and IV (7.5-minute infusion) amifostine, in which the SC route provided lower toxicity as well as better bioavailability of the active drug form of amifostine. 13 Preliminary data have been reported in a trial of radiation for squamous cell head and neck tumors with SC or IV amifostine as a cytoprotectant. Nausea and vomiting, skin rash, asthenia, and xerostomia were comparable in the SC and IV arms. Hypotension was 6% in the IV arm versus 0% in the SC arm, while compliance with amifostine administration was 70% in the IV arm and 80% in the SC arm. 14 A trial comparing intrarectal versus SC administration for abdominal radiotherapy found that intrarectal amifostine gave better results for acute radiation rectal mucositis but that SC amifostine gave better results for urinary mucositis. 15 Results of a phase II trial of SC amifostine for head and neck radiotherapy were compared to results of a phase III trial of IV amifostine in the same setting. 16 Outcomes for xerostomia were similar. Nausea, vomiting, and hypotension were less frequent with SC than with IV amifostine, but skin toxicity was more frequent. A pharmacoeconomic study found that 500 mg amifostine, given SC, did not reduce radiation mucositis sufficiently to offset the higher costs for administration, although the authors speculated that a higher dose of amifostine might have prevented hospitalization from mucositis enough to make the higher cost worthwhile. 17 A randomized clinical trial has been designed to compare the IV and SC routes in chemoradiation therapy for lung cancer, their impact on esophagitis, and the ability of SC delivery to improve the full delivery of amifostine doses in this setting. 18 Other studies, as mentioned below, continue to explore this apparently promising alternative means of drug delivery.
Clinical Studies and Continuing Controversies
Despite the initial problems with toxicities and logistical drawbacks of amifostine administration, research proceeded. Most clinical studies showed no evidence of tumor protection. The development of treatment regimens with very serious side effects, such as chemoradiation and high-dose conditioning with chemotherapy or radiation prior to bone marrow transplant, spurred researchers to extend their areas of interest to these settings. Based on large randomized studies, FDA approval was granted in 1995 for an im-portant reduction of renal damage related to cisplatin at standard chemotherapeutic doses for ovarian and non-small-cell lung cancer (NSCLC). Approval was granted in 1999 for reducing xerostomia in postoperative chemoradiotherapy for head and neck cancer.
The study on which the latter approval was granted fueled the controversy about amifostine and tumor protection. Brizel et al used amifostine with 303 patients receiving radiation for previously untreated head and neck cancer, with locoregional control a primary antitumor end point, along with toxicity reduction. 19 Amifostine significantly reduced grades 2 to 4 acute xerostomia from 78% to 51% and chronic xerostomia grades 2 to 4 from 57% to 34%. Median saliva production was also greater with amifostine, although there was not a reduction in mucositis. With and without amifostine, 2-year locoregional control was 58% versus 63%, and overall survival was 71% versus 66%. Controversy about reliance on this study for FDA approval for the indication of radiation-induced xerostomia led to a head-to-head debate between Brizel and respected Danish radiation oncologist Jens Overgaard on the role of amifostine in chemoradiation in the pages of Lancet Oncology in 2003. 20 A key point in this debate was the ability of randomized trials to detect tumor protection. A single randomized trial, even a fairly large one, such as that of Brizel, lacks the ability to detect small degrees of tumor protection. Even a small percentage of tumor protection by a cytoprotectant such as amifostine could negate the curative potential of cancer therapy for thousands of patients, if the cytoprotectant was widely used. Brizel summarized the debate, noting that to detect a survival reduction from 45% to 40% in the head and neck cancer scenario, with 80% statistical power, a study that would require 1246 patients per arm would be needed-a waste of funding and patient resources. Such a study would also be highly unlikely in that the largest randomized head and neck trial ever performed took 8 years to enroll 1113 patients. Brizel acknowledged the problems with amifostine delivery and with the lack of certainty provided by such a trial. However, he argued, in view of the many smaller randomized trials in which tumor protection did not appear and the proof of principle that amifostine reduced toxic effects of treatment without compromising efficacy, it would be foolish to ignore the development of this potentially valuable tool. Overgaard, on the other hand, speculated that the recent spate of clinical trials of amifostine in chemoradiation resulted from its being bought by a new manufacturer anxious to improve on its investment in the drug and emphasized the reviews of preclinical studies showing repeated instances of tumor protection. He also pointed out the FDA's caution that amifostine should not be administered in curative therapeutic settings and that data on the safety and efficacy of amifostine in chemoradiation still were, in fact, lacking. He concluded by stating that "the absence of evidence is not evidence of absence," certainly a statement that must be acknowledged by all researchers. Still, we would add, the absence of evidence is also not the evidence of presence of tumor promotion.
Clinical Practice Guidelines
Alongside the continuing controversies surrounding amifostine, both the United States and Canada have published clinical practice guidelines on its use. US guidelines were first published in 1999 by the American Society of Clinical Oncology (ASCO), and they were updated in 2002, discussing both chemotherapy and radiotherapy. 21 These guidelines can be summarized as follows:
• Amifostine may be considered to prevent nephrotoxicity in cisplatin-based chemotherapy (1999 A further clarification of these guidelines was provided in a letter from the ASCO committee, which stated that the use of amifostine in curative settings for radiotherapy of head and heck cancer should not be undertaken lightly because it is unlikely that clinical trials of sufficient size can be assembled to rule out the possibility of tumor protection. 22 This letter also stated that the ASCO guidelines did not cover the situation of chemoradiation.
The most recent guidelines are those concerning amifostine and chemotherapy from Canada, which were published in 2003 by the National Guideline Clearinghouse, based on a review of trials published through September of 2002. 23 These include the following:
• Amifostine is a reasonable therapeutic option when using doses of cisplatin greater than 100 mg/m 2 or when high cumulative cisplatin doses are used (greater than 600 mg/m 2 ) to reduce neurotoxicity, ototoxicity, or nephrotoxicity. No data indicate whether similar benefits are produced at lower doses of cisplatin, but amifostine could be considered at doses greater than 300 mg/m 2 . • Amifostine is one reasonable therapeutic option to reduce myelosuppression. In assessing its impacts on quality of life, especially in palliative treatment, its acute toxic effects need to be weighed against its ability to reduce morbidity from neutropenic fevers. • There is no evidence to justify the routine use of amifostine to improve survival by maintaining the dose of chemotherapy agents.
In discussing a study of ovarian cancer in which treatment-limiting toxicity was less in the amifostine arm than in the control arm, the Canadian group made the interesting comment that "overall doseintensity of the chemotherapy on the amifostine arm was higher compared with the control arm. If this is so, then the lack of difference in efficacy [in tumor response or survival rate between the amifostine and control arms] is at least consistent with some degree of tumor protection by amifostine. However, alternative explanations are possible." 23(p17) They went on to conclude, though, that even with a higher dose intensity and possibly some degree of tumor protection in the amifostine arm, there was, ultimately, no trade-off in diminished efficacy and that amifostine improved the therapeutic index of the cytotoxic agents. Improvement of the therapeutic index of highly toxic regimens based on chemotherapy and/or radiation is, certainly, the motivation of most investigators who have subsequently explored amifostine, in all awareness, after the comments of Brizel and Overgaard, that some degree of tumor protection may be involved. As more trials of amifostine in different settings become available, it is possible that meta-analysis may eventually be able to resolve the question of whether amifostine has any tumor-protective abilities and their significance, if such are found.
Recent Research: Amifostine and Chemotherapy Regimens
What have clinical studies shown since the publication of the clinical practice guidelines summarized above? To explore the directions that research in this area has taken since the publication of the latest guidelines, we have assembled a set of clinical studies of amifostine and chemotherapy (including chemoradiation and high-dose chemotherapy in stem cell transplant settings) that have been published since the latest studies included in the Canadian guidelines. Rather than providing a systematic review of this literature with an aim to suggest modifications to current guidelines, these studies are examined to show what indications for antioxidant cytoprotectants may be found to be reasonable in current or upcoming research, in what areas amifostine seems to be emerging as a feasible option, and in which areas it does not seem to provide useful support. Areas for potential research on phytochemical cytoprotection may emerge from this consideration, especially in light of both amifostine's toxicity and its gaps in effective cytoprotection.
Recent studies of amifostine included 13 in which it was studied in the context of chemotherapy (standard or higher dosage) without radiation or bone marrow transplant. These studies are shown in Tables 1 and 2 . Table 1 summarizes the methodology of each study, including drug dosages, while Table 2 summarizes major results of the study. Table 2 includes an overall evaluation of each study as (1) positive for normal tissue protection (indicating that side effects of the cancer treatment regimen were less than expected or less for an amifostine treatment group than for a control group), (2) null for normal tissue protection, (3) clinically significant amifostine side effects observed, or (4) a combination of the previous evaluations. Evaluations were made by the reviewers, based on comments and recommendations made by the authors of each study. Differences discussed are significant unless otherwise noted. Table 1 provides a summary of some of the settings in which the ability of amifostine to ameliorate chemotherapy side effects was explored. The dosage of amifostine used in these studies was variable. The most frequently used dosage was 740 mg/m 2 , used in 5 studies, while 3 studies used the higher 910 mg/m 2 . Amifostine was given intravenously in 11 studies, while it was given subcutaneously and as an oral rinse in 1 study each. A variety of different premedication regimens and other supportive strategies during amifostine administration was reported. Typically it was given for 15 minutes before one of the chemotherapy agents used in the study, and dexamethasone as well as antiemetics, hydration, withholding of usual antihypertensive medication, and/or supine positions during infusion were used to improve tolerability. In 10 of the studies, multiple-agent (2-3 agents) chemotherapy protocols were used. High doses of cisplatin were used in 2 studies, while 1 study explored the possibility of dose increases of idarubicin and 1 study examined the use of amifostine in patients who had difficulty tolerating chemotherapy for colorectal cancer due to excessive diarrhea.
Thongprasert and Chewaskulyong used amifostine in a single-group study with cisplatin and vinblastine in patients with locally advanced or metastatic NSCLC (Tables 1 and 2) . 24 Cisplatin was used at a dose of 100 mg/m 2 , as platinum-based chemotherapies have widely been found to provide statistical improvements in survival and disease-related symptoms. In this group of 41 patients, a 38% partial response rate and a 33week median survival were observed. Grade 3 to 4 toxicities were observed, including leukopenia, thrombocytopenia, anemia, hypertension, and neuropathy, although they were generally present in low percentages of patients; no high-grade renal toxicity was observed, consistent with other studies in which amifostine protected against cisplatin-induced nephrotoxicity. Data were insufficient to evaluate amifostine-induced protection against thrombocytopenia, neurotoxicity, or ototoxicity, but the general evaluation of the regimen was positive for normal tissue protection.
Ekborn et al studied high-dose cisplatin (125-150 mg/m 2 ) in patients with stage IV malignant melanoma (Tables 1 and 2) . 25 In addition to studying the occurrence of cisplatin-related ototoxicity, previously indicated to be one of amifostine's possible protective effects, these authors investigated the pharmacokinetics of cisplatin and its active metabolite, referred to as monohydrated complex (MHC). The pharmacokinetic investigation was undertaken in part to determine whether amifostine affected cisplatin pharmacokinetics and in part to determine whether pharmacokinetic parameters could be used to predict ototoxicity in individuals. A group of 15 patients was studied prospectively. Cisplatin treatment ended prematurely in 4 patients because of ototoxicity or nausea and vomiting; in the remaining patients, it was discontinued because of disease progression. No objective responses were observed, and median survival after initiation of chemotherapy was 6 months. Amifostine had no effect on auditory symptoms, with 92% of patients reporting auditory problems. Three patients required hearing aids after therapy. The authors commented that amifostine is generally not thought to protect the brain or spinal cord due to the blood-brain barrier. A similar barrier exists for the inner ear. In addition, while there is alkaline phosphatase activity in some inner ear structures, the hair cell in the organ of Corti, which is the target organ of cisplatin-related ototoxicity, is remote from the blood circulation. Ekborn et al also noted an effect of amifostine on the pharmacokinetics of cisplatin. They observed that the dose-normalized area under the curve (AUC) value for cisplatin and MHC was lower in this group than had been found in a reference group, possibly (with or without) Amifostine 740 mg/m 2 , n = 37; IV 15 min prior to paclitaxel no amifostine, n = 34 Kanat et al, 2003 37 Randomized, NSCLC III-IV Paclitaxel 175 mg/m 2 IV every 21 d n = 38
Carboplatin AUC = 6 IV every 21 d Amifostine 910 mg/m 2 , n = 19; IV 15 min, before paclitaxel no amifostine, n = 19 NSCLC = non-small-cell lung cancer; IV = intravenous; SC = subcutaneous; AUC = area under the curve; G-CSF = granulocyte colonystimulating factor; 5FU = 5-fluorouracil.
because of an intracellular interaction between cisplatin and the active amifostine form, WR-1065. Finally, they did not observe any correlation between the AUC or peak concentration of cisplatin and hearing loss, potentially due to a large intraindividual variation in sensitivity to these high doses of cisplatin. Overall evaluation of amifostine performance was null for normal tissue protection, and significant amifostine side effects were observed.
A study to determine whether liposomal doxorubicin could successfully be added to the chemotherapy regimen of docetaxel and gemcitabine in NSCLC was conducted by Patlakas et al (Tables 1 and 2) . 26 Amifostine, given SC, and granulocyte colony-stimulating factor (G-CSF) were included in the regimen in consideration of the poor performance status of most lung cancer patients at the time of chemotherapy. Twenty chemotherapy-naïve patients were included in the study, of which 18 were evaluable. The study showed a 33% response rate and median survival of 11 months. Grade 3 palmar-plantar erythrodysesthesia was observed in 30% of patients, grade 2 mucositis/ esphagitis in 15%, and mild alopecia in 30%; no interstitial pneumonia was observed. The negligible level of thrombocytopenia observed was attributed to the activity of amifostine. The lower level of palmarplantar erythrodysesthesia might have been due in part to the split dose of liposomal doxorubicin. Overall evaluation is positive for normal tissue protection in this study of SC amifostine.
Moore et al conducted a phase II study of amifostine in the setting of women with ovarian, peritoneal, fallopian tube, endometrial, or cervical cancer receiving cisplatin and paclitaxel chemotherapy ( Tables 1 and 2) . 27 Grade 3 peripheral neuropathy was observed in 3 of 27 evaluable patients, and grade 2 31 Percentages of patients with pneumonia (18%), sepsis (10%), fever of unknown origin (31%), and infections (60%) were similar to those observed in a prior study of the same regimen without amifostine. Null. Stokman et al, 2004 32 Oral mucositis assessment scale, World Health Organization toxicity grade, mucositis pain, swallowing and feeding difficulties were not significantly different between rinse and control cycles. Null. Tsavaris et al, 2003 33 Improvements in hematological toxicity, increase in dosage of 5-fluorouracil that could be administered, less mucositis with amifostine. Highest amifostine dose eliminated diarrhea, but 76% of patients had hypotension. Lowest dose led to 17% grade 1 diarrhea and 25% hypotension. Positive. Amifostine side effects observed at higher dosage levels. De Vos et al, 2005 34 Median progression-free survival 23 mo with and 16 mo without amifostine. Small but significant reduction in grade 2 nausea and vomiting. Grade 2 sensory neuropathy in 2% with and 12% without amifostine. No differences in quality-of-life questionnaire. Positive, though small, effect. Glover et al, 2003 35 Response rate 23% with and 16% without amifostine. 1 lethal, 2 life-threatening, and 1 severe episode of renal toxicity in amifostine group. 46 severe or worse toxic events in amifostine group and 43 in control; amifostine group experienced more overall toxicity. Null. Amifostine side effects observed. Hilpert et al, 2005 36 Significant protective effect of amifostine was observed on objective measurements of neuropathy and toxicity grades; patient-rated skillfulness was better. Overall quality of life was similar between amifostine and placebo groups, but nausea and vomiting were worse in amifostine group. Null. Amifostine side effects observed. Kanat et al, 2003 37 Response rate 37% with and 34% without amifostine. Grade 1-2 paresthesia in 42% with and 95% without amifostine. Grade 2 sensory motor impairment in 10% with and 47% without amifostine. No grade 3-4 neurotoxicity and no cardiotoxicity in either group. Positive.
neuropathy was observed in 1 patient, despite chemotherapy dose reductions and amifostine. This was beyond the threshold calculated to proceed with second-stage patient accrual, and the study was thus discontinued. Evaluation of the performance of amifostine was null for normal tissue protection. A phase II trial of amifostine used with paclitaxel and carboplatin in the treatment of advanced, recurrent, or refractory endometrial cancer was reported by Scudder et al (Tables 1 and 2) . 28 Most patients had previously undergone surgery (94%), and more than half underwent radiotherapy to the pelvis. With an 8% complete response (CR) rate and a median progression-free survival of 7 months, the combination performed satisfactorily in this difficult population. The main toxicity observed was hematological, with 79% of patients experiencing grades 3/4 neutropenia. Despite this high incidence, there were no episodes of grade 4 febrile neutropenia and only 1 infection. No grade 3/4 sensory neuropathy was observed. Amifostine was tolerated fairly well, with 3 of 47 patients developing grade 3 nausea and 2 patients grade 3 vomiting. Overall results of the regimen were considered positive for normal tissue protection, as the authors concluded that this combination is a reasonable option in selected patients in this clinical setting.
Polyzos and colleagues conducted a Phase II study of salvage therapy in anthracycline-resistant breast cancer patients using paclitaxel and vinorelbine (Tables 1 and 2 ). 29 They observed a 33% response rate and 8-month median survival and commented that this indicates a lack of cross-resistance between this chemotherapy combination and anthracyclines. Despite use of SC amifostine and G-CSF, 35% of patients developed grade 3 to 4 neutropenia, although no grade 3 to 4 neuropathy was observed. While the performance of amifostine was moderately positive for normal tissue protection, the use of amifostine and G-CSF was not considered cost-effective, and the authors do not plan to include these drugs in the chemotherapy regimen in the future.
A study to determine whether the use of amifostine would allow dosage escalation of idarubicin for patients with acute myelogenous leukemia (AML; Tables 1 and 2) was conducted by Grosso et al. 30 The clinical outcome of AML is worse for patients older than 60 years at diagnosis, especially since they often lack tolerance for the rigorous regimens needed to obtain complete remission. AML also can exhibit a more resistant and aggressive phenotype in these patients. Thus, the authors gave idarubicin at doses of 12, 13, 15, 17, 19, 21 , and 24 mg/m 2 to successive cohorts of patients, provided that no patient at any given dose experienced grade 3 or 4 nonhematologic toxicity. A 61% CR rate was observed. Among 34 patients, 5 experienced grade 3 mucositis at idarubicin doses of 21 and 24 mg/m 2 . No patients had grade 3 or 4 diarrhea or congestive heart failure. Eighteen percent experienced bacteremia. These results were considered positive for normal tissue protection, and the authors stated that 21 mg/m 2 idarubicin might be tested in more patients of all ages. Vigorous prehydration and withholding of regular antihypertensive medication prior to administration of amifostine allowed for all the doses of amifostine to be completed.
A study of a fludarabine and cyclophosphamide regimen by Giles et al (Tables 1 and 2) examined the use of amifostine with this regimen, given for chronic lymphocytic leukemia (CLL). 31 Because CLL patients are immunosuppressed, and additional myelosuppression by chemotherapy can result in high rates of sepsis and mortality, the authors wished to determine whether the reduction in myelosuppression previously observed with amifostine for other cyclophosphamide regimens would have value in this instance. Rates of pneumonia, sepsis, fevers of unknown origin, and early death were similar to those observed in prior studies without amifostine, as were rates of objective response. The authors thus concluded that amifostine did not reduce the toxicity of this regimen in CLL patients, and the overall evaluation of the performance of amifostine was null.
The dephosphorylated form of amifostine, WR-1065, was used in an oral rinse in a study to determine whether local cytoprotection would diminish oral mucositis in NSCLC patients treated with epirubicin (Tables 1 and 2). Stokman et al converted the prodrug form of amifostine, WR-2721, ex vivo to WR-1065, which was incorporated into a mouthwash at a dosage of 125 mg. 32 The mouthwash was given on cycles 2 and 3 of up to 5 cycles of epirubicin. Questionnaires and evaluations including an oral mucositis assessment scale (OMAS), World Health Organization toxicity grade, mucositis pain, and determination of swallowing and feeding difficulties were performed as well as sampling to determine cellular concentration of WR-1065 in the oral mucosa. In no case were there differences between the control cycle (cycle 1) and the rinse cycles. In part, this might be due to low occurrence of mucositis in the first cycle (21% grade 2 or more, though greater than 35% was expected). No patients experienced grades 3 or 4 mucositis during the entire treatment period. In addition, in only 50% of the patients did the cellular concentration of WR-1065 reach the calculated effective cellular concentration. A negative correlation was observed between the concentration of WR-1065 and the OMAS scale. The authors conceded that the tested concentration of WR-1065 is ineffective in preventing epirubicininduced mucositis but suggested that ways of increasing cellular concentrations (eg, higher rinsing frequency, extended rinsing time, higher WR-1065 concentration) might be effective in raising cellular concentrations and preventing mucositis. Overall the evaluation was null for the performance of amifostine in normal tissue protection at the tested concentration.
Tsavaris and colleagues explored the use of amifostine with 5-fluorouracil (5FU) and folinic acid in advanced colorectal cancer (Tables 1 and 2) . 33 This regimen commonly results in high rates of diarrhea, mucositis, and hematological toxicity. The study of Tsavoris et al examined whether a range of doses of amifostine could be used to diminish diarrhea in patients undergoing 5FU chemotherapy who were experiencing unacceptable levels of diarrhea, without incurring excessive amifostine toxicity (hypotension, nausea, vomiting, and consequent dose reduction). Successive groups of 18, 16, and 18 patients were given amifostine in doses of 800 mg/m 2 , 500 mg/m 2 , and 150 mg/m 2 before weekly 5FU. Supportive measures taken during administration of amifostine are not detailed in the publication. The highest dose of amifostine completely eliminated diarrhea, while the lower doses allowed only the development of grade 1 diarrhea. Results for incidence of mucositis were also favorable, and hematological toxicity was lower. A higher dose of 5FU could be administered to patients receiving amifostine, due to lack of need for dose reductions. However, at the highest dose of amifostine, 76% of patients experienced some degree of hypotension. At the lowest dose of amifostine, the maximal diarrhea grade observed was grade 1 (17% of patients), and only 25% of patients experienced hypotension. The authors regard these results positively and recommend randomized studies to determine whether low-dose amifostine can be used to prevent severe 5FU-related diarrhea. The performance of amifostine was positive for normal tissue protection; significant amifostine side effects were seen at the higher concentrations tested, though not the lower. Overall performance of amifostine was positive but limited for normal tissue protection.
De Vos and colleagues report a randomized phase II study of amifostine in the setting of first-line therapy for advanced ovarian cancer using paclitaxel and carboplatin treatment (Tables 1 and 2 ). 34 They noted that while the amifostine group did better than the control group (grade 2 neurotoxicity in 3 amifostine vs 12 control patients and grade 3 in 4 vs 5 patients and 1 vs 3 treatment discontinuations), there was less absolute protection from higher grades of toxicity than would be desirable; they found a positive but small effect. They pointed out that cisplatin-induced neuropathy is based on alkylation, which may be more susceptible to amifostine activity than paclitaxelinduced neuropathy, which results from inhibition of tubulin depolymerization. No effect on myelotoxicity was seen. Amifostine was tolerated fairly well with 5 temporary interruptions due to hypotension and a 6% to 8% incidence of grade II nausea and vomiting, but no dose reductions were necessary. Overall performance of amifostine was positive but limited for normal tissue protection; significant amifostine-related side effects were not seen.
A randomized phase II trial was conducted by Glover and colleagues using amifostine 910 mg/m 2 with cisplatin for patients with metastatic melanoma (Tables 1 and 2 ). 35 In this trial, amifostine with cisplatin doses of 120 mg/m 2 or 150 mg/m 2 was contrasted with cisplatin alone at its maximal single-agent dose of 120 mg/m 2 to determine whether amifostine would allow higher doses of cisplatin to be administered. The response rates with and without amifostine were 23% and 16%. There were 1 lethal, 2 life-threatening, and 1 severe episodes of renal toxicity in the amifostine group. Overall there were 46 severe or worse toxic events in the amifostine group and 43 in the control group. The higher dose of cisplatin was more toxic, even with amifostine, than the lower dose without; 9 of 11 grade 4 toxic events were observed in this group. The response rate was not higher in the high-dose cisplatin group. To some degree, the increased toxicity of the higher dose of cisplatin was observed in cases of protocol violation, omission of adequate hydration after cisplatin early in the study, administration of other nephrotoxic drugs, and admission of patients with extensive liver metastases into the study; these were resolved later in the study, and hydration was given both before amifostine and after cisplatin treatment. The evaluation of amifostine in this trial was null for normal tissue protection, and clinically significant amifostine adverse effects were seen.
Hilpert and colleagues evaluated amifostine in a double-blind, placebo-controlled trial in ovarian cancer patients receiving carboplatin and paclitaxel, with or without epirubicin (Tables 1 and 2) . 36 Most trials of amifostine have lacked the placebo-controlled condition; it was instituted in this trial because of the relatively small number of patients (72) and the large number of subgroups necessary with the addition of the epirubicin present or absent condition. Objective assessments of neurotoxicity were used (2-point discrimination, vibration perception threshold, vibration disappearance threshold) in addition to toxicity grading and patient questionnaires. While there were definite improvements in neurotoxicity according to the clinical toxicity grading and objective measurements, as well as for patient assessments of skill and of sensory neuropathy on quality of life questionnaires, overall quality of life was not better in the amifostine group. Nausea and vomiting were significantly worse in the amifostine-treated patients, despite premedication with dexamethasone and an H2 receptor antagonist. The performance of amifostine was positive for normal tissue protection, but clinically significant amifostine side effects were seen and apparently worsened quality of life.
Kanat et al observed the effects of amifostine on myelosuppression, neurotoxicity, and cardiotoxicity in patients receiving a paclitaxel-carboplatin regimen for NSCLC in a randomized trial. 37 Electroneuromyography, echocardiography, and regular audiography were performed to detect paresthesias, cardiotoxicity from paclitaxel, and ototoxicity from carboplatin. Hematological effects were similar in the 2 groups. Paresthesias of grade 1 to 2 and grade 2 sensory motor impairment were less in the amifostine group, although no clinical grade 3 or 4 impairment was seen in either group. The mean motor conduction velocity of the right peroneal nerve for nonamifostine patients declined significantly after 6 cycles of treatment while that of the amifostine group did not. Only transient episodes of cardiotoxicity were seen in both groups, and there were no reports of vertigo, tinnitus, or hearing loss; audiologic parameters were similar between the groups and from baseline through the sixth cycle of chemotherapy. Overall evaluation of the performance of amifostine was positive for normal tissue protection, and amifostine was thought to contribute to lower rates of neurotoxicity due to paclitaxel.
Overall, 8 of the chemotherapy studies, as summarized in Table 2 , were evaluated as showing positive effects of amifostine or effects that were positive but with some qualifications. Of the 3 randomized studies (which were not large, with sample sizes ranging from 72 to 94), 1 was evaluated as showing effects that were positive but small and 2 had negative evaluations. It should be particularly noted that in no case was the survival or response rate of amifostine-treated patients significantly less than that of control patients or less than usual expectations. In 1 case of significant amifostine side effects, protocol violations, insufficient hydration, and problems with inclusion criteria may have contributed to the higher rates of toxicity observed. In another case, a null evaluation arose from high rates of nausea and vomiting due to amifostine, resulting in a lower quality of life than would have been expected from the improved neuropathy ratings and objective measurements found in the study. The variation in degrees of amifostine toxicity (nausea, vomiting, hypotension) found in different studies suggests that substantial attention must be paid to adequate pharmacological and physical support of patients undergoing amifostine treatment. Subcutaneous administration or other modes of delivery may play a role in improving amifostine's usefulness in these situations; neither of the 2 studies of SC amifostine observed clinically significant side effects, although 1 observed only moderate protection of normal tissues and did not find amifostine (together with G-CSF) to be cost-effective. Intriguing results in nonrandomized studies suggest that the study of amifostine for particular indications deserves further examination. These include studies of patients unable to tolerate 5FU therapy, salvage therapy in anthracycline-resistant breast cancer patients, and dosage increase with idarubicin therapy for AML patients. Notably, all 3 of these situations involve administration of amifostine to patients who are known or likely to have problems with tolerance of chemotherapy regimens.
Studies of Amifostine With Chemoradiation
Amifostine was used with chemoradiation in 9 recent studies reviewed here. Table 3 summarizes the methodology of each study, while Table 4 reviews the results and offers overall evaluation.
In each of the studies reviewed, a platinum-based therapy was a component of the treatment regimen (as shown in Table 3 ); 6 studies included multiple chemotherapy agents. Amifostine was administered by IV or IV push before radiation in 4 studies, before chemotherapy in 3 studies, and before either chemotherapy or radiation in 2 studies, 1 of which was a case series in which amifostine administration was tailored to the patients. Amifostine doses ranged from 250 mg flat doses to 910 mg/m 2 . Hyperfractionated radiotherapy schedules were used in 3 studies.
Vacha et al studied the use of amifostine in chemoradiation with head and neck cancer patients in a small randomized trial (Tables 3 and 4 ). 38 Mucositis, usually a common and severe problem with such protocols, was less throughout the study in the amifostine group and significantly less in week 2. However, rates of severe mucositis in this trial were less than often reported, with only 8% of patients in both the control and amifostine groups, respectively. This may have been due to use of conformational irradiation techniques. Xerostomia was significantly less with amifostine during weeks 2 and 4 of the trial, and salivary gland toxicity was less with amifostine. The authors tempered the overall positive evaluation of the effect of amifostine on normal tissue protection by pointing out the lack of blinding in the evaluation of the patients and the potential for sparing the salivary glands by use of better radiotherapeutic techniques instead of more expensive radioprotectors such as amifostine. They reported that the type of prior surgical neck dissection, which contributes to xerostomia, was balanced between the 2 groups, a variable that is often missing in reports of xerostomia studies.
Suntharalingam et al presented results of a small phase II study of amifostine with chemoradiation in squamous cell cancer of the head and neck (Tables 3  and 4 ). 39 While there have been advances in treatment of this cancer, they have come with a high price tag in terms of toxicity: in a prior trial, these investigators found 70% grade 3 mucositis, 30% grade 3 skin irritation, and 100% grade 2 or higher xerostomia. They paid particular attention to the problem of missed treatments in reporting on this trial, in addition to reporting rates of toxicity. Seventy-five percent of patients in the trial had CR. Grade 3 mucositis and dysphagia were observed in 40% of patients and grade 3 xerostomia in 20%. Other grade 3 toxicities included dermatitis (20%), dehydration (27%), and leukopenia (53%). At least 90% of planned amifostine doses were received in the case of 56% of patients, with the usual reason for missed doses being chemoradiation toxicity rather than amifostine toxicity. The entire prescribed radiation series and more than 6 cycles of chemotherapy were received by 84% of patients, and 40% of patients had no unscheduled treatment breaks. These results, while still indicating a high range of treatment-related toxicity, represent an improvement on the results these authors found with a similar regimen without amifostine. They commented that the dose of amifostine they used, a flat 500 mg, was higher than some other trials that have used doses of about 200 mg/m 2 and have not found improvements in mucositis with head and neck cancer (although some amifostine-related toxicity was observed). Overall evaluation of the performance of amifostine is positive for normal tissue protection and indicates an improvement of the therapeutic index of the regimen by decreasing its toxicity.
Kutter and colleagues also studied chemoradiation of locally advanced squamous cell head and neck cancer (Tables 3 and 4 ). 40 They commented on the need for frequent treatment breaks and the problems this imposes, including the possibility of tumor cell repopulation between treatments. Most chemoradiation schedules for this disease had been able to deliver only 2 full cycles of a single-agent chemotherapy regimen along with standard fractionation radiation. The aim of their study was to attempt to deliver 3 cycles of standard chemotherapy along with accelerated radiation therapy. They also attempted to reduce the overall time from diagnosis to treatment by beginning the first cycle of chemotherapy immediately after diagnosis, while radiation therapy planning and required dental care were taking place. Thus, chemotherapy cycles began soon after diagnosis, while radiation treatment started at the beginning of the second cycle of chemotherapy. Amifostine was given before each chemotherapy dosage, that is, 3 times. In this intensive regimen, all but 2 of 23 patients received the full dose of radiation therapy, and 78% achieved CR. Overall survival at 45 months was 56%. A reversible grade 2 or higher renal insufficiency was observed in 39% of patients; all patients had grade 2 to 3 mucositis, and 19 patients had grade 3 skin toxicity. Neutropenic fever was observed in 39% of patients. The authors commented that although the regimen did appear feasible with toxicity that was high but manageable, it is rather difficult to evaluate the contribution of only 3 doses of amifostine given with chemotherapy. Daily infusion of amifostine before radiation therapy is, they point out, costly and labor intensive and so was omitted from this trial. However, the survival rate of 56% after nearly 4 years with the overall regimen is encouraging. Overall evaluation of the performance of amifostine is positive for normal tissue protection, although somewhat limited. Recurrences of squamous cell cancer of the head and neck in patients who have previously received radiotherapy can be difficult to manage and often lethal. Reirradiation was previously considered to be infeasible but has begun to be considered. A pilot study was undertaken by Machtay et al to determine whether the use of fractionated radiation therapy and amifostine in previously irradiated head and neck cancer patients with locally advanced recurrences was possible (Tables 3 and 4 ). 41 Accelerated, hyperfractionated radiation therapy with treatments given twice daily was used, and amifostine was given before either the morning or the afternoon treatment daily. A 63% overall survival at 3 years was recorded in the 16 patients in this pilot study. All patients completed radiotherapy and at least 1 cycle of chemotherapy. The regimen was well tolerated acutely, although 19% of patients had nonneutropenic infections that were successfully treated. Grade 3 mucositis/pharyngitis occurred in 7 patients and grade 2 in 9. All patients were able to complete the intensive program without treatment interruptions or dose-limiting toxicity. However, 3 patients had severe late events: a fatal stroke, a nonfatal stroke, and a life-threatening hemorrhage. The combination of the large daily total dose of radiation plus concurrent chemotherapy may have contributed to the late effects. The authors commented that other studies of reirradiation have also shown cases of fatal vascular events. The small size of the study could not allow conclusions about how useful amifostine was in the reirradiation setting. Because many reirradiation patients present with some degree of chronic radiation toxicity from their initial radiation treatments, it is possible that further antioxidant protection might be necessary to reduce late toxicities. Overall the performance of amifostine was positive for normal tissue protection in the acute setting but not long term.
Commentary on Amifostine
The first of 3 studies of amifostine in chemoradiation of NSCLC was conducted by Komaki et al (Tables 3 and 4 ). 42 Chemoradiotherapy of NSCLC has been explored in several studies and found to improve survival times but carries with it a high risk of severe toxicity, especially in elderly patients. These investigators had previously used a chemoradiation protocol based on cisplatin and etoposide that had a favorable long-term outcome (26% 5-year survival) but a high rate of grade 3 and 4 esophagitis. Amifostine was thus used with this regimen, given twice weekly to minimize logistical difficulties but before chemotherapy and radiation whenever both modalities were used together to maximize cytoprotection. The randomized study of 62 patients found that median survival times were similar with and without amifostine (19 and 20 months) but that grade 3 and 4 esophagitis was 35% without and 16% with amifostine. Severe pneumonitis was observed in 16% of patients without and 0% of patients with amifostine, while neutropenic fevers were found in 39% of patients without and 16% of patients with amifostine. Sneezing and hypotension were more frequent with amifostine but were mild. Overall evaluation of the performance of amifostine is positive for normal tissue protection, and the authors suggest larger scale randomized trials of this regimen.
Movsas et al found that the quality-adjusted survival (QAS) of induction chemotherapy followed by radiation therapy was nearly the same as that of concurrent chemotherapy and radiation in an analysis of large lung cancer studies. 43 Reducing the esophageal, upper gastrointestinal, and lung toxicities led to the greatest improvement in QAS of concurrent therapy. Thus, Movsas et al designed a study (RTOG 98-01) to determine whether addition of amifostine to a schedule of induction chemotherapy with carboplatin and paclitaxel followed by concurrent chemotherapy and hyperfractionated radiotherapy would increase the tolerability of concurrent therapy (Tables 3 and 4 ). 44 Amifostine was given IV 4 times weekly during concurrent therapy. Of the 120 patients in the study receiving amifostine, only 72% received the full doses as prescribed; rates of acute nausea and vomiting, cardiovascular toxicity, and infection or neutropenia were higher with amifostine. No differences were seen with rate of grade 3 to 4 esophagitis, survival, or overall quality of life. However, patient diaries reported significantly less swallowing dysfunction with amifostine, and pain was improved at 6-week follow-up. While the evaluation of the role of amifostine in the study was negative, these intriguing results present some encouragement to further pursue the role of amifostine in concurrent chemoradiation for NSCLC using another dosing route such as subcutaneous dosage, which seems to result in less toxicity. Performance of amifostine in normal tissue protection in this study was questionable, and clinically significant amifostine side effects were observed.
The third study of NSCLC was performed by Antonadou et al (Tables 3 and 4 ). 45 This randomized phase II study investigated whether daily pretreatment with amifostine reduced esophagitis and late lung toxicities with conventional radiation and concurrent paclitaxel or carboplatin administration. Patients received daily radiation therapy along with weekly carboplatin or paclitaxel; amifostine was given before chemotherapy on chemotherapy/radiotherapy days and before radiation on radiation-only days. Rates of response (CR + partial response) were similar in the 2 groups: 82% without amifostine and 89% with amifostine. Grade 3 to 4 esophagitis was seen in 38.9% of patients with and 84.4% of patients without amifostine; grade 3 to 4 acute lung toxicity was seen in 19.4% of patients with and 56.3% of patients without amifostine. Pneumonitis at 3-month follow-up was found in 30% of patients with and 67% of patients without amifostine, and rates of fibrosis at 6-month follow-up were nonsignificantly lower in amifostine patients. An overall high incidence of esophagitis in the trial was attributed to the large number of stage IIIb patients who were treated with large radiation fields, more likely to affect the radiosensitive esophagus. Patients who also received amifostine were able to complete the chemoradiation treatment without interruptions. Overall evaluation of the performance of amifostine in normal tissue protection is positive.
Treatment of pediatric medulloblastoma with chemoradiation has permitted an improved eventfree survival rate of 85% but results in hearing loss in up to 48% of patients and renal toxicity in up to 21%, making the option of a cytoprotectant such as amifostine of substantial interest. Fisher et al performed a pilot study of amifostine in chemoradiation in this setting with 11 patients (Tables 3 and 4 ). 46 While 5-year survival was adequate in the treated patients, 78% had some degree of significant ototoxicity and 56% had grade 3 renal toxicity, although none had grade 4. Only 22% of patients received the full planned cisplatin dose, due to side effects. The authors felt that amifostine, although well tolerated in this population, did not prevent cisplatin-related toxicities. Overall performance of amifostine in normal tissue protection in this study is null.
An intriguing case series was reported by Nguyen et al (Tables 3 and 4 ). 47 Seven cases of significantly compromised cancer patients who were elderly, had comorbitidies including AIDS, or who needed very large irradiation fields were discussed. Such patients are typically left out of chemoradiation clinical studies with curative intent as they are felt to be intolerant of concurrent therapies. They are offered either no therapy or palliative therapy, in some cases giving rise to the appearance of discrimination due to the prevalence of AIDS and advanced cancers in minority populations. Nguyen et al treated a series of such patients with chemoradiation involving cisplatin and 5FU, with amifostine and careful supportive therapy. Comorbidities in addition to AIDS included hepatitis, congestive heart failure, cardiomyopathy, hypertension, stroke, diabetes, and severe arthritis. Tumors involved were in the anus, base of the tongue, esophagus, and soft palate. Each patient achieved a complete response. Various patients experienced improvements in quality of life, including resumption of oral feeding in a patient with severe dysphagia. Evaluation of the role of amifostine in these patients is positive for normal tissue protection. The potential relevance of this case series study should not be underestimated. Although it is not a randomized trial, it demonstrates the possibility of extending potentially curative regimens and reasonable improvements in quality of life to populations who usually suffer from marked undertreatment of their cancers.
Of the 9 studies in this group, 7 were positive for normal tissue protection or had positive but limited outcomes, 1 had a null outcome, and 1 had a questionable outcome, with patient assessments disagreeing with those of toxicity grading, stimulating further exploration of amifostine. Clinically significant amifostine side effects were observed in 1 study. Four studies were randomized; of these, 3 had positive results, and the fourth (and largest) was the study in which patient reports were more positive than toxicity grading. Positive studies in both head and neck cancer and lung cancer were found. Response rates and survival times were similar in amifostine and control groups or else similar to expected results in nonrandomized studies. The case series study is intriguing in addressing the needs of potentially undertreated populations. In these cases, which would not have received chemoradiation protocols without a cytoprotectant, the issue of tumor protection is moot. The potential clinical benefits in this setting warrant further research.
Studies of Amifostine With High-Dose Chemotherapy Conditioning for Bone Marrow Transplant
Amifostine was used with high-dose chemotherapy in 6 recent studies reviewed here. Table 5 summarizes the methodology of each study, while Table 6 reviews the results and offers overall evaluation.
Amifostine doses in 4 of the studies were 740 mg/ m 2 , while lower and higher doses were used in 1 study each. In each case, amifostine was given prior to chemotherapy by IV for 10 to 15 minutes. Busulfan was used in 2 studies, cyclophosphamide in 2 studies (1 with busulfan), and melphalan in 2 studies.
Hwang et al undertook a study of amifostine in allogeneic bone marrow transplants for patients with various leukemia and lymphoma-related conditions, based on studies that had indicated that it reduced toxicity in conditioning regimens for autologous hematopoietic stem cell transplantation (Tables 5 and  6 ). 48 This randomized but open-label study gave amifostine patients single doses when total-body irradiation or chemotherapy was given to patients once daily. The dose was divided when patients received chemotherapy or radiation more than once a day. A 37% 3-year survival was noted with or without amifostine, and days to neutrophil or platelet engraftment were similar. Some aspects of toxicity, specifically duration of grades 1 to 4 mucositis, grades 3 to 4 infections, and antibiotic and fever duration, were significantly lower with amifostine, and these were considered of great importance by the authors. However, there was no difference in the incidence of grades 3 to 4 mucositis or renal or liver toxicity, perhaps in part due to the long half-life of some of the chemotherapy drugs given compared to that of amifostine. In high-dose chemotherapy regimens with allogeneic grafts, there are some different considerations relating to excessive cytoprotection from those in standard chemotherapy, autologous transplants, and chemoradiation. Certainly, there is the question of whether cancerous cells are affected more by conditioning than normal cells are. However, there is also a question of whether the recipient's lymphocytes are protected so thoroughly that they would be likely to reject the donor allograft. Thus, neutrophil and platelet engraftment times were specifically monitored in the amifostine and control group. In this study, amifostine did not block the immunosuppressive effect on the lymphocytes, as the 2 groups had similar engraftment times. The overall effect of the amifostine was considered positive but modest for normal tissue protection.
Because of conflicting results in prior studies of amifostine and paclitaxel-induced neuropathy, Openshaw et al undertook to study amifostine in the setting of high-dose conditioning chemotherapy. 49 They studied breast cancer patients on 2 protocols, 1 with and 1 without amifostine (Tables 5 and 6 ). Detailed neurophysiological testing was performed on both groups, as was pharmacokinetic analysis. There were no differences in paclitaxel pharmacokinetics in AUC, maximum concentration, or systemic clearance. Narcotic use and recovery of the hematopoietic system were also similar. The detailed neurophysiological testing as well as clinical evaluation of neuropathy showed that the 2 groups did not differ significantly. Evaluation of the performance of amifostine was null for normal tissue protection.
Benesch et al also evaluated whether amifostine would protect against toxicities in the allogeneic stem cell transplant setting in a small study of 12 patients with advanced myelodysplastic syndrome (MDS) or AML evolved from MDS (Tables 5 and 6 ). 50 One patient had CR, and median time to platelet engraftment was considered normal. However, 8 of 12 patients died of non-relapse-related causes within 3 months of the transplant. All patients had mucositis; 6 had pulmonary toxicity and 6 liver toxicity. The trial was closed after 12 patients. Overall evaluation of performance of amifostine in normal tissue protection was null.
The optimal chemotherapy conditioning regimen to use for non-Hodgkin lymphoma and Hodgkin lymphoma patients undergoing autologous hematopoietic stem cell transplant is still a matter of some controversy. One component of some current regimens is melphalan. While doses of melphalan greater than 200 mg/m 2 are associated with severe regimen-related toxicity, Phillips et al have been exploring the escalation of melphalan doses to as high as 300 mg/m 2 in the context of conditioning regimens. They evaluated whether amifostine might contribute to controlling the toxicities of such high-dose regimens in a phase I to II trial (Tables 5 and 6 ). 51 A total of 26 patients who had received extensive prior treatment were entered into the trial. Of these, 22 survived to the first posttransplant evaluation, and 13 had CRs. Median survival in the study was 286 days. Toxicity was manageable, with only grade 1 toxicity in 15 patients and grade 2 in 8. One patient each had cardiac and hepatic toxicities at the highest doses used. Overall performance of amifostine in normal tissue protection was positive. The authors believe that additional studies using high-dose melphalan and amifostine are justified and that amifostine may be useful in the setting of the combination chemotherapy regimens that are most commonly used.
Thieblemont et al studied high-dose melphalan in the setting of multiple myeloma treatment with autologous peripheral blood progenitor cell transplant (Tables 5 and 6 ). 52 The dose used, 200 mg/m 2 , was less than that attempted by Phillips et al. A nonrandomized study of patients who agreed and who refused to participate in a trial of amifostine was carried out. Oral mucositis was less in the amifostine group, as was delayed vomiting. No differences were found in hematological toxicity or recovery. In the amifostine group, 10 of 21 patients had CR, whereas only 4 of 20 patients without amifostine had CRs. No severe effects were found from administration of amifostine, and the authors concluded that amifostine may reduce mucositis in this combination and could be examined in a phase III trial. Overall performance of amifostine in normal tissue protection was positive.
A similar drug regimen and cancer was studied by Spencer et al (Tables 5 and 6 ). 53 Multiple myeloma patients receiving their first autologous stem cell transplant received high-dose melphalan with amifostine (at a higher dose than in Thieblemont et al's study). A randomized study was conducted that monitored outcomes related to mucositis. Percentages of patients with complete responses did not differ significantly, with 30% in the amifostine arm and 14% in the control arm; the latter value was lower than usually observed but still certainly not exceeding the rate in the amifostine arm. The median grade of mucositis was significantly lower in the amifostine arm, as was the incidence of grades 3 to 4 and 2 to 4 mucositis. However, the duration of mucositis and required parenteral nutrition and narcotics did not differ between groups. Variables related to engraftment and supportive therapy were similar, as were progressionfree survival and overall survival at 35 months of follow-up. Overall performance of amifostine was positive in normal tissue protection, though somewhat limited.
In this group of 6 studies, 4 had positive effects, although in 2 the effect was somewhat limited. The performance of amifostine in both of the small randomized studies was regarded positively. One of the studies is interesting for demonstrating the possibility of safely elevating melphalan dosages substantially above those usually used, with the support of amifostine. As in the previous types of studies, survival rates or CR rates did not differ between amifostine and control groups in randomized studies or were similar to expected values in nonrandomized studies.
Commentary on Amifostine

Discussion
In this series of clinical studies involving more than 1300 patients, in randomized, nonrandomized comparative, and single-group studies, results of work on amifostine are generally favorable. Overall, 19 protocols involving amifostine used with chemotherapy, chemoradiation, or high-dose chemotherapy and bone marrow transplant were positive for normal tissue protection, 9 were null, and 1 had a questionable evaluation based on differences between subjective and objective responses. Of the randomized trials in the group, 7 found positive results for amifostine, 2 null results, and 1 questionable result. In every case, the response rate or survival time associated with amifostine was either the same as or better than the result associated with no amifostine. In the case of singlegroup studies, the survival time or response rate results were as expected for the particular cancers under investigation. A wide range of drugs was used in the studies, though platinums and taxanes predominated. On this basis, amifostine certainly holds some promise as a cytoprotectant in today's rigorous conventional cancer treatments. The symptoms reported in different studies varied. Positive results in mucositis were reported in 10 studies, while 3 reported null results. The positive results were associated with a variety of chemotherapy drugs including the combinations carboplatin and paclitaxel; docetaxel, doxorubicin, and gemcitabine; idarubicin and ARA-C; cisplatin and 5FU; busulfan and cyclophosphamide; and the single-drug treatments of 5FU, carboplatin, and melphalan. Positive results with esophagitis/dysphagia were reported in 4 studies, while 1 reported null results. The positive results were associated with the regimens carboplatin and paclitaxel, cisplatin and etoposide, and docetaxel, doxorubicin, and gemcitabine. Positive results with neuropathy were reported in 3 studies, while 1 study reported null results. Positive results were associated with paclitaxel-based regimens in 2 studies and with cisplatin and vinorelbine in 1 study, while 1 paclitaxelbased regimen was associated with null results. Results in other side effects were mixed, null, or small in number: nausea and vomiting (2 positive/2 null for amifostine protection of normal tissue), cisplatin ototoxicity (2 null), cardiotoxcity (3 positive), diarrhea (2 positive), hematological (4 positive/4 null), lung toxicity (3 positive/2 null), quality of life (1 positive/1 null), xerostomia (2 positive), and other toxicities (skin: 1 null, liver: 2 positive/1 null, renal: 1 null).
However, the picture of amifostine is by no means entirely benign and positive. In various studies, it was associated with renal toxicity, nausea and vomiting (sometimes as high as grade 3), hypotension, other cardiovascular effects, and infections. While most patients tolerated the drug well, every study reported some patients who had to stop the drug (dropout rates were generally not as high as those reported by Rades et al 10 ). Of note, the trials of pediatric patients and compromised or elderly patients reported that amifostine was well tolerated. In 1 study (Hilpert et al 36 ), the subjective and objective measurements of neuropathy were significantly better in the amifostine than the placebo group, but nausea and vomiting were worse in the amifostine group, so that the qualityof-life score (which assessed both neuropathy and nausea/vomiting in addition to other variables) did not differ significantly: amifostine's side effects, when given IV in this study, are seen neutralizing its benefits in overall life quality. As noted above, however, the use of SC administration of amifostine appears to substantially reduce the toxicity due to hypotension, nausea, and vomiting, at least in the available early-stage studies of this alternative method of drug delivery. Reducing the toxicity of amifostine will substantially change its therapeutic index, and the overall evaluation of some clinical trial settings, should the SC route continue to exceed the IV route in further studies.
The general direction of recent research on amifostine has focused on studies that seek to improve the therapeutic index of the chemotherapy and other components of the progressively harsher regimens now in use in cancer therapy, with a view to improving the ability of a broader range of patients to tolerate them. While some of the regimens are used in a curative setting, the issue of tumor protection was seldom raised beyond the preliminary discussion sections, probably in part because those studies that provided comparative survival or response outcomes found them to be either equal or nonsignificantly in favor of amifostine, which has been the common outcome throughout the history of human studies on amifostine. The effort to broaden the accessibility of these regimens to compromised patients was specifically mentioned in some studies, for example, that of Nguyen and colleagues in elderly or compromised cancer patients or that of Grosso and colleagues, 30 which specifically mentions the goal of producing a regimen with high doses of idarubicin that are tolerable by patients older than 60 years, who both have difficulty in tolerating conventional regimens and tend to have aggressive tumors that are resistant to more typically used regimens. Several of the studies also mentioned recruiting patients from among those in their institutions who were ineligible for other trials involving curative regimens.
Cytoprotection, Tumor Protection, and Antioxidants
Using cytoprotectants in what are considered curative regimens is likely to be regarded with continuing suspicion because of the possibility of tumor protection. For some physicians, this will remain the case until trials with thousands of patients per arm disprove the element of tumor protection in several regimens. Running studies of the required size is a decidedly unlikely possibility, given the many competing needs in oncology research today. This is true whether the tumor protection has been indicated as a possibility, as in the case of the study of Bairati et al on α-tocopherol and β-carotene, 2 or whether no obvious indications of tumor protection have arisen in clinical trials to date, as in the case of amifostine.
How relevant is the research on amifostine for the use of other antioxidants, especially phytochemical antioxidants, alongside cancer therapies? While the study of Bairati et al 2 has raised some questions on the part of many practitioners about the wisdom of allowing any patients to use any antioxidants during therapy, there is certainly more to be learned about the phytochemical antioxidants and how they actually work in the body. Kennedy et al, for instance, reported that in pediatric acute lymphoblastic leukemia patients receiving chemotherapy, patients with higher plasma levels of several antioxidants experienced fewer dose reductions, fewer infections, improved quality of life, less delay in chemotherapy treatment schedule, reduced toxicity, and fewer days spent in the hospital. 54 It is certainly true that amifostine possesses unique chemical properties that lead to its concentration in normal tissues, and it remains unclear whether it may also engender some degree of tumor protection. The special properties of amifostine are not shared by phytochemical antioxidants as far as we know, but interesting data are emerging that suggest that the antioxidant properties of these compounds are not their only activities. Conklin has recently suggested that during cancer chemotherapy, lipid peroxidation induced by oxidative stress results in the generation of aldehydes that slow the cell cycle and even cause cell cycle arrest. 55 Cell cycle arrest would interfere with the cytotoxic properties of chemotherapy agents, as most of these kill only actively dividing cells. Administering antioxidants during therapy would tend to reduce this oxidative stress and thereby improve the cytotoxic ability of chemotherapy drugs. A recent study by Chen et al examined the anticancer properties of ascorbic acid. 56 At concentrations that could be achieved only by IV administration of ascorbate-typical of several alternative cancer regimens-ascorbate selectively killed cancer cells, which were sensitive to < 4 µM. Normal cells were untouched at concentrations 5 times as high. The mechanism of cell death appeared to be generation of hydrogen peroxide. While this does not speak directly to the ability of ascorbic acid to engage in tumor protection during cancer therapy, it does point out some surprising and selective properties of this well-known antioxidant. It may also help to explain the good results reported by Drisko et al for 2 ovarian cancer patients who used multiple antioxidants with and high-dose intravenous vitamin C following their chemotherapy regimens. 57 Jatoi et al surveyed 1129 lung cancer patients about their use of vitamins and minerals and followed up the population for survival after lung cancer diagnosis. 58 The patients who used vitamins and minerals had a median survival of 4.3 years versus a survival of 2.0 years for nonusers, as well as a higher quality of life than nonusers. That the users were more likely to be nonsmokers and women and that they had a higher proportion of earlystage tumors suggest that they may have, in fact, had good general health habits and been long-term users of vitamins and minerals and thus perhaps used them through the course of cancer therapy, although this cannot be determined from the study. It is possible that in some therapeutic settings, vitamins and minerals, perhaps in combination with good health habits, may contribute to an overall improvement in performance status that outweighs any tumor-protective effects.
As important as curative regimens are in much of oncology, though, there is another realm of oncology in which tumor protection is less of an issue. This can arise from 2 situations in cancer care, both of which are relevant in integrative cancer therapy.
In the first situation, we find that the use of cytoprotectants, even potentially tumor-protective ones, is quite reasonable and perhaps mandatory for several categories of patients: (1) those who are unable to tolerate conventional regimens (such as those studied by Tsavaris et al 33 who had excessive diarrhea during adjuvant chemotherapy); (2) those whose adjuvant therapy regimens have failed them and left them with poor performance status, compromising their tolerance for further therapy; (3) patients with metastatic disease, whose only options are salvage or palliative therapies, even though their overall performance status may be adequate; (4) those whose age or extent of disease places them at high risk for adverse effects, such as those studied by Nguyen et al 47 and Grosso et al 30 ; and (4) those who are simply too anxious and frightened of conventional therapies to submit to them and who would otherwise forego useful treatments in favor of undertaking alternative therapies (which might be useful supports in some circumstances but may not be suited to primary control of tumor growth). Integrative practitioners will recognize each of these types of patients in their clinics, in addition to those patients who are in relatively good health and who are aggressively interested in improving it or in preserving their performance status throughout cancer treatment as they pursue other important life goals.
The second situation in which tumor protection may be less of a problem-which may follow the first situation or may be undertaken following a curative regimen in a relatively sound patient population-is one in which a tumor-controlling treatment such as chemotherapy or radiation is followed with an aggressive program of lifestyle intervention, supplement use, and use of appropriate conventional drugs such as tamoxifen or the modern molecular target therapies, which generally stabilize or contain rather than eliminate tumors. This situation is similar to one mentioned by Camphausen et al, in an editorial response to the article of Bairati et al, 2 in which they suggest that studies of antioxidant cytoprotectants during radiotherapy be conducted in settings in which there is a high rate of successful salvage therapy. 59 In these cases, patients unwilling to undergo conventional treatment without cytoprotectants, even ones that may entail some degree of tumor protection, may be enabled to extend survival through continuing disease stabilization rather than only curative treatment. Containment of tumors and control of their growth are a main proposition of integrative therapy. This idea is certainly in need of testing in clinical trials, although suggestive evidence that nutritional factors may prolong survival or reduce factors that can promote recurrence has been published. Rock et al, for instance, in a recent review, found that obesity and treatmentrelated weight were associated with poor prognosis and shorter disease-free survival, while intake of fruits and vegetables had a direct relationship with survival. 60 Rock et al also reported that in a randomized trial, breast cancer patients who were instructed in a low-fat, high-fiber, and high-vegetable and -fruit diet had lower serum bioavailable estradiol levels at 1-year follow-up, even in the absence of significant weight loss. 61 Given the population that usually arrives at integrative and alternative therapy clinics, the strategy of following conventional treatment with nutritional and other support is one that is presently implemented daily, on the basis of informed physician judgment and patient interest and desire.
The real question is whether integrative practitioners, perhaps, should simply use the existing cytoprotectants, such as amifostine and others. While we feel that the answer is yes, in that they should certainly be used-and we do actively use them when they are appropriate in our clinic-these drugs are simply not the only answer to the problem of optimal cytoprotection. Amifostine is, as has been pointed out previously, expensive, difficult to administer, and prone to causing a variety of toxicities. While it seems to be effective in several types of toxicities, such as mucositis arising from a number of different chemotherapy drugs, it certainly does not address all the toxicity problems of contemporary cancer treatment.
The search for clinically useful cytoprotectants, as well as antioxidant therapies administered after conventional treatments to promote survival or address late effects of conventional therapy, should continue, and phytochemical antioxidants should be part of it. Other clinical research in this area has been reported, involving compounds or combinations such as superoxide dismutase, melatonin, α-tocopherol, or pentoxifylline with α-tocopherol, some with promising results, which must nevertheless be regarded as preliminary, based on small sample sizes and study design. [62] [63] [64] [65] [66] [67] The results recently published by Bairati et al 2 should not be taken as an indication that no antioxidant substances or foods should ever be taken by anyone during or after conventional therapy, although that conclusion is likely to be drawn by any number of conventional physicians. In fact, not unlike Pathak's study 4 of antioxidants and chemotherapy, our own preliminary data on metastatic breast cancer patients who received chemotherapy with antioxidant support at our clinic indicate that, in contrast to antioxidants interfering with conventional treatment strategies, outcomes are better with the use of antioxidants. Rather, while we wait for further research to answer whether, or how best, to use antioxidant cytoprotectants in curative regimens, researchers should consider which diseases and regimens are most in need of well-tolerated, oral antioxidant regimens that may offer cytoprotection of normal tissues and in which some potential of tumor protection may be acceptable to extend the possibility of useful tumorcontrolling treatment to some of the populations mentioned above, in case future research does support, in a particular situation, the as-yet undetermined concern of tumor protection. Possibly more important, the potential for improvement in treatment efficacy by the use of antioxidants during treatment must also be further explored. 55 Phytochemical antioxidants, or the botanical radioprotectants that have been discussed in studies published in this journal and elsewhere, 68, 69 should be evaluated in these regimens using proper methodology, beginning with animal trials or with small human trials and then proceeding to larger randomized studies. The goal of eliminating the possibility of tumor protection in such regimens, while important, should be subsidiary to the goal of improving the therapeutic index of regimens that meet the needs of the huge population of cancer patients for whom modern tumor-controlling chemotherapy regimens are intolerable, unfeasible, or simply unacceptable.
